The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE
OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
ARVINAS INC COM 04335A105 23,595 287,251 SH   SOLE   287,251 0 0
C4 THERAPEUTICS INC COM STK 12529R107 12,103 375,857 SH   SOLE   375,857 0 0
CULLINAN ONCOLOGY INC COM 230031106 18,842 1,221,145 SH   SOLE   1,221,145 0 0
EQRX INC COM 26886C107 89,372 13,104,424 SH   SOLE   13,104,424 0 0
KINNATE BIOPHARMA INC COM 49705R105 53,306 3,008,243 SH   SOLE   3,008,243 0 0
KRONOS BIO INC COM 50107A104 19,726 1,451,537 SH   SOLE   1,451,537 0 0
PMV PHARMACEUTICALS INC COM 69353Y103 32,012 1,385,807 SH   SOLE   1,385,807 0 0
REVOLUTION MEDICINES INC COM 76155X100 74,710 2,968,214 SH   SOLE   2,968,214 0 0
SILVERBACK THERAPEUTICS INC COM 82835W108 12,721 1,910,029 SH   SOLE   1,910,029 0 0
THESEUS PHARMACEUTICALS INC COM 88369M101 7,751 611,310 SH   SOLE   611,310 0 0
TYRA BIOSCIENCES INC COM 90240B106 35,436 2,518,582 SH   SOLE   2,518,582 0 0